Great Lakes Advisors LLC purchased a new stake in Cardinal Health, Inc. (NYSE:CAH - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 15,357 shares of the company's stock, valued at approximately $3,648,000.
Other hedge funds have also modified their holdings of the company. Integrated Wealth Concepts LLC raised its holdings in shares of Cardinal Health by 6.9% during the first quarter. Integrated Wealth Concepts LLC now owns 4,363 shares of the company's stock valued at $601,000 after acquiring an additional 280 shares during the period. Jones Financial Companies Lllp lifted its holdings in shares of Cardinal Health by 198.3% in the first quarter. Jones Financial Companies Lllp now owns 21,112 shares of the company's stock valued at $27,000 after purchasing an additional 14,034 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Cardinal Health in the second quarter worth $1,935,000. Cerity Partners LLC grew its holdings in shares of Cardinal Health by 17.0% during the second quarter. Cerity Partners LLC now owns 40,426 shares of the company's stock valued at $6,792,000 after buying an additional 5,880 shares in the last quarter. Finally, Nebula Research & Development LLC raised its position in Cardinal Health by 34.4% during the second quarter. Nebula Research & Development LLC now owns 10,334 shares of the company's stock valued at $1,736,000 after buying an additional 2,646 shares during the period. 87.17% of the stock is owned by hedge funds and other institutional investors.
Key Headlines Impacting Cardinal Health
Here are the key news stories impacting Cardinal Health this week:
- Positive Sentiment: Royal Bank of Canada initiated coverage of Cardinal Health with a “moderate buy” or outperform-equivalent rating. RBC cited the integration of higher-margin services as a potential driver of future earnings outperformance. RBC Capital Starts Cardinal Health at Outperform
- Positive Sentiment: A Zacks analysis identified CAH as a potentially attractive long-term value stock, while recent coverage has highlighted Cardinal Health’s precision-medicine operations and higher-margin services as sources of sustained growth. Why Cardinal Health Is a Top Value Stock for the Long-Term
- Neutral Sentiment: Brokerages continue to assign Cardinal Health a consensus “moderate buy” rating. The constructive view is tempered by valuation and questions about the sustainability of recent earnings gains.
- Negative Sentiment: Multiple executives and insiders sold shares around $235–$237. Chief Executive Officer Jason Hollar sold a combined 124,529 shares worth approximately $29.4 million, while CEO Deborah Weitzman sold about $1.7 million. Other insider sales included Chief Accounting Officer Mary Scherer and executives Michelle Greene, Jessica Mayer, and Stephen Mason. The transactions substantially reduced several executives’ holdings and may signal that insiders are taking profits after the stock’s strong rally. Cardinal Health Insider Sale Filing
- Negative Sentiment: Although Cardinal Health reported adjusted quarterly EPS of $2.91, well above the $2.42 consensus, an analysis noted that a significant portion of the earnings improvement came from a one-time tariff refund. That raises concerns about the durability of the earnings beat and may be contributing to the weaker stock performance. Cardinal Health Earnings Analysis
Wall Street Analysts Forecast Growth
A number of brokerages have commented on CAH. Morgan Stanley raised their price objective on Cardinal Health from $255.00 to $265.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 12th. William Blair started coverage on shares of Cardinal Health in a research report on Tuesday, April 28th. They issued an "outperform" rating for the company. Citigroup raised their price target on shares of Cardinal Health from $265.00 to $280.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Robert W. Baird boosted their price objective on shares of Cardinal Health from $251.00 to $274.00 and gave the company an "outperform" rating in a research report on Wednesday, August 12th. Finally, Royal Bank Of Canada began coverage on shares of Cardinal Health in a research report on Wednesday. They issued an "outperform" rating and a $276.00 target price for the company. Sixteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $266.56.
View Our Latest Report on CAH
Cardinal Health Trading Down 2.5%
CAH stock opened at $228.95 on Friday. The firm has a market cap of $53.25 billion, a PE ratio of 31.67, a PEG ratio of 1.26 and a beta of 0.49. Cardinal Health, Inc. has a 1 year low of $145.87 and a 1 year high of $258.30. The company has a fifty day simple moving average of $231.91 and a 200 day simple moving average of $217.78.
Cardinal Health (NYSE:CAH - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.42 by $0.49. Cardinal Health had a negative return on equity of 98.53% and a net margin of 0.67%.The company had revenue of $63.67 billion for the quarter, compared to analyst estimates of $65.15 billion. During the same period last year, the company earned $2.08 earnings per share. The business's revenue was up 5.8% compared to the same quarter last year. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. As a group, analysts forecast that Cardinal Health, Inc. will post 12.54 EPS for the current fiscal year.
Cardinal Health Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be issued a $0.5158 dividend. This represents a $2.06 annualized dividend and a yield of 0.9%. The ex-dividend date is Thursday, October 1st. Cardinal Health's payout ratio is 28.49%.
Insider Activity
In other Cardinal Health news, CEO Deborah Weitzman sold 7,354 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $235.45, for a total transaction of $1,731,499.30. Following the transaction, the chief executive officer owned 77,901 shares in the company, valued at $18,341,790.45. This trade represents a 8.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jessica L. Mayer sold 29,436 shares of the business's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $236.19, for a total transaction of $6,952,488.84. Following the completion of the sale, the insider owned 33,076 shares of the company's stock, valued at $7,812,220.44. The trade was a 47.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 210,271 shares of company stock valued at $49,626,657. Insiders own 0.12% of the company's stock.
Cardinal Health Company Profile
(
Free Report)
Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.
The company's core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Cardinal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardinal Health wasn't on the list.
While Cardinal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
